Biotech chairman: ”It will hopefully set an example”
Martin Bonde, the chairman of the industry association, Dansk Biotek, considers the forthcoming IPO of Orphazyme to be “extremely exiting”. He hopes that this development can contribute to ushering other Danish biotech companies onto the Danish stock market.
BY MARTIN HAVTORN PETERSEN
The Danish biotech company, Orphazyme ended months of speculationon Tuesday morning, by officially announcingits first step towards an Initial Public Offering (IPO) as it sent a so-called Intention to Float notification to Nasdaq Copenhagen.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Denmark sees first IPO of a biotech firm since 2010
For abonnenter
